Sesen Bio Inc

Sesen Bio — Eleven Biotherapeutics — Investor Presentation (January 2017)

42 slides from Sesen Bio's investor presentation, Jan 6, 2017

  1. Slide 1: January 2017 Corporate Overview

    January 2017 Corporate Overview

  2. Slide 2: Forward-looking statements

    This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, clinical development of our protein thera

  3. Slide 3: Recent Developments

    Recent Developments • Eleven Biotherapeutics (Eleven) is a clinical stage company engineering and developing protein-based therapeutics for human disease • On August 16th, 2016 Eleven completed an exclusive licensing deal for EBI- 031 with Roche ‒ EBI-031 is a humanized monoclonal antibody that pote

  4. Slide 4: Company Highlights

    Company Highlights • Eleven is now a clinical stage oncology company developing Targeted Protein Therapeutics (TPTs) ‒ TPTs are single fusion protein constructs with a differentiated payload mechanism, eliminating the need for payload conjugation and expensive multi-step manufacturing ‒ Designed to

  5. Slide 5: Product Pipeline

    Product Pipeline Product Candidate Payload Indication Pre-clinical Ph 1 Ph 2 Ph 3 Locally-administered TPTs Vicinium ETA BCG refractory high-grade NMIBC Proxinium in combination with Checkpoint Inhibitor ETA Late-stage SCCHN Systemically-administered TPTs VB6-845d deBoug Solid tumors Partnered Asset

  6. Slide 6: Experienced Leadership Team

    Experienced Leadership Team Steve Hurly President, CEO, and Director Arthur DeCillis, MD Chief Medical Officer John McCabe, CPA Chief Financial Officer Greg Adams, PhD Chief Development Officer Glen MacDonald, PhD Chief Scientific Officer Wendy L. Dixon, PhD Chair Abbie C. Celniker, PhD Paul Chaney

  7. Slide 7: Antibody Drug Conjugates

    Antibody Drug Conjugates ADC payloads are not well matched to the cancer they are developed to treat ̶ typically subject to multidrug resistance (MDR) mechanisms* ̶ Not active against cancer stem cells Many ADCs suffer from unstable chemical linkers between the antibody and drug ̶ Unstable linkers c

  8. Slide 8: TPTs Designed to Overcome Limitations and Improve on Existing ADCs

    TPTs Designed to Overcome Limitations and Improve on Existing ADCs TPTs: • Designed to deliver a greater amount of drug to the tumor bed with deeper penetration ‒ Engineered utilizing antibody fragments (single chains and Fabs) • Designed to kill a broader array of cancer cells within a targeted tum

  9. Slide 9: Fit for Purpose TPT Design

    Fully biologic constructs that are designed through recombination of key components as single gene-fused proteins One Targeting Moiety + Linker + Protein toxin Furin Cleavable Non- Cleavable scFv Fab Diabody DeBouganin ETA (Pseudomonas Exotoxin A) Designed for loco-regional delivery Vicinium and Pro

  10. Slide 10: Treatment of High-Grade NMIBC

    Treatment of High-Grade NMIBC 10

  11. Slide 11: Vicinium: Loco-Regional Delivery

    Vicinium: Loco-Regional Delivery Truncated Pseud. exotoxin A (ETA) C ̶ Binds specifically to EpCAM-positive cells ̶ Enters cell after binding to EpCAM ̶ Minimal to no EpCAM expression on normal bladder cells ̶ EpCAM over-expressed in high grade NMIBC ̶ Potent payload ̶ Requires antibody binding to e

  12. Slide 12: Vicinium: Mechanism of Action

    Vicinium: Mechanism of Action 12

  13. Slide 13: Vicinium: Treatment of High-Grade NMIBC

    Vicinium: Treatment of High-Grade NMIBC • Bladder Cancer - 2nd most common cancer of genitourinary system ‒ Ninth most common cancer diagnosed worldwide (~430,000 new patients/year)* ‒ In the U.S., bladder cancer has the highest per patient treatment costs • Indirect costs of $184,762 to $461,907 pe

  14. Slide 14: Vicinium: Expanded indications

    Vicinium: Treatment of High-Grade NMIBC Expanded indications - In addition to the initial BCG refractory market, we believe Vicinium may have applications in the following additional indications: • Retreatment: Patients who respond to Vicinium and subsequently have a recurrence, could potentially ha

  15. Slide 15: Vicinium: Phase 1 Clinical Results

    Vicinium: Phase 1 Clinical Results • 64 patients with Grade 2 or 3 BCG refractory or intolerant+ NMIBC* • Trial design • Treated weekly x 6 weeks: Dose escalation (0.1- 30.16 mg) • Efficacy assessment: Cystoscopy, Biopsy (Random and Directed), Urine Cytology *Source: Kowalski et. al., Drug Design, D

  16. Slide 16: Vicinium: Phase 2 Clinical Results

    Vicinium: Phase 2 Clinical Results • 46 post BCG refractory or intolerant carcinoma in situ (CIS) subjects* • Refractory or intolerance to one or more courses of BCG in the prior 24 month • CIS is most aggressive form, toughest to treat NMIBC population • Induction phase: 30mg in 40mL for 6 or 12 we

  17. Slide 17: Vicinium: Phase 2 Clinical Results

    Vicinium: Phase 2 Clinical Results CIS with or without Ta, T1 CIS with or without Ta, T1 Treatment Arm B Subjects (N=20) Treatment Arm A Subjects (N=20) 6 Week Induction 12 Week Induction 73% of the non CRs showed reduction in tumor or stable disease relative to % area affected at baseline Increased

  18. Slide 18: Adverse Events: Phase 1 and 2 Trials

    Adverse Events: Phase 1 and 2 Trials • No significant toxicity or tolerability issues ‒ Generally well tolerated ‒ No subjects unable to complete treatment • Phase 1 Trial ‒ 31% of subjects experienced an AE related to treatment ‒ 98% of all AEs were Grade 1 or 2 ‒ Incidence of AEs decreased with in

  19. Slide 19: Phase 3 Study of Intravesical Vicinium

    An Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Tolerability of Intravesical ViciniumTM in Subjects with Non Muscle Invasive Carcinoma in Situ (CIS) and/or High-Grade Papillary Disease of the Bladder Previously Treated with Bacillus Calmette Guérin (BCG) 19

  20. Slide 20: Vicinium Study in Bladder Cancer (VISTA)

    Vicinium Study in Bladder Cancer (VISTA) • Following the guidance provided by FDA, we commenced an open-label, non- randomized Phase 3 clinical trial of Vicinium in subjects with BCG refractory/relapsed high-grade NMIBC in the United States and Canada in Q3 2015 • Targeted to enroll 134 subjects (77

  21. Slide 21: Response Evaluation

    Response Evaluation • Week 13 (Post-Induction Phase) and every 13 weeks • Evaluation includes cystoscopy and urine cytology • Biopsies (directed) required if suspicious lesions are found on cystoscopy • Random biopsies may be required if urine cytology suspicious for high grade urothelial carcinoma

  22. Slide 22: NMIBC – Recent events

    NMIBC – Recent events • Sanofi BCG announcement – November 17th, Sanofi plans to stop producing BCG in mid-2017 saying it hasn’t been able to restore full production at a Toronto manufacturing plant that had contamination problems. • Relevance: No expected impact on Vicinium Phase 3 trial however li

  23. Slide 23: Treatment of Late-Stage SCCHN

    Treatment of Late-Stage SCCHN 23

  24. Slide 24: Proxinium: Targeting Late-Stage Squamous Cell Carcinoma Head & Neck

    Proxinium: Targeting Late-Stage Squamous Cell Carcinoma Head & Neck • Single chain anti-EpCAM fragment fused with ETA to treat late-stage SCCHN • Late-stage SCCHN is dominated by the primary tumor ‒ 40-60% of deaths result from local or regional disease* ‒ 90% of patients with disseminated disease d

  25. Slide 25: Proxinium Phase I Studies

    Proxinium Phase I Studies VB4-101 VB4-101A Location Russia Brazil Schedule Daily x 5 Q 28 days Weekly x 4 MTD 200 µg 700 µg N 24 20 EpCAM positive 17 18 Response Criteria – based on target lesion(s) • Investigator’s measurements • Investigator’s overall assessment including qualitative changes • Ind

  26. Slide 26: Proxinium: Phase 1 Clinical Trial Results

    Proxinium: Phase 1 Clinical Trial Results • EpCAM expression was not an inclusion criterion • EpCAM positive subjects were 71% (Russia) and 90% (Brazil) • None of the evaluable EpCAM-negative subjects (n=8) from either trial responded • Three out of the four patients with complete responses had regr

  27. Slide 27: Proxinium: Targeted & Non-Targeted Responses

    After four weeks of treatment Targeted tumor cell cytotoxicity may lead to cross-priming and immune therapy (T cell-mediated killing) of non-targeted tumors Injected Tumor Subject A: Subject B: Pre-treatment Injected Tumor Non-Targeted Tumor Proxinium: Targeted & Non-Targeted Responses 27

  28. Slide 28: Proxinium: Phase 1 Trial

    Proxinium: Phase 2 Trial • Reduction in the bidirectional size of the principle targeted tumor observed in 71% (10/14) of the evaluable subjects • RECIST criteria not employed • In 5 subjects with multiple tumors, growth control of the initial treated tumor was achieved in 4/5 subjects leading to tr

  29. Slide 29: Proxinium: Phase 2/3 Trial Efficacy in Late-Stage SCCHN

    Proxinium: Phase 3 Trial Efficacy in Late-Stage SCCHN • Randomized 2 arm trial - Proxinium + Best Supportive Care (BSC) vs. BSC • Phase 2 lead-in rolled into Phase 3 • EpCAM-positive, refractory late-stage SCCHN • 700 mg of Proxinium administered weekly via intratumoral injection • Treated until CR

  30. Slide 30: Proxinium: Phase 2/3 Clinical Trial Data

    Proxinium: Phase 2/3 Clinical Trial Data Proxinium + BSC vs. BSC summarized Phase 2 and Phase 3 data* RECIST criteria not employed Progression Stable Disease Response *Only subjects with baseline and post-treatment tumor measurements are included (N = 36 for Proxinium + BSC; N = 26 for BSC only). 30

  31. Slide 31: Immune Checkpoint Combinations

    Immune Checkpoint Combinations • Clinical trials suggest that Proxinium may be promoting host anti-tumor immune responses • Immune checkpoint therapy requires an ongoing immune response ‒ Effective in “hot” (inflamed) tumors often associated with somatic mutations • Immune Cell Death (ICD)* ‒ Promot

  32. Slide 32: Proxinium: ICD-induced DAMPs

    Proxinium: ICD-induced DAMPs Proxinium mediates ICD and induces DAMPs suggesting that it could promote host cellular anti-tumor immune responses Control Proxinium VB4-4B5 9 hrs 5.7 ± 0 8.8 ± 0.1 5.8 ± 0.3 18 hrs 10.3 ± 0.3 17. 05 ± 0.35 10.5 ± 0.1 36 hrs 9.75 ± 0.25 21.65 ± 0.55 11.5 ± 0.1 NT Proxin

  33. Slide 33: Preclinical Assessment with a Checkpoint Inhibitor

    Preclinical Assessment with a Checkpoint Inhibitor • Immunodeficient myeloablated NOG mice engrafted with human bone marrow stem cells. Mice implanted with contralateral EpCAM “+” PDX tumors and effect of Proxinium on injected tumors and uninjected tumors alone or in combination with a PD-1 inhibito

  34. Slide 34: Proxinium: Proposed Clinical Development Plan

    Proxinium: Proposed Clinical Development Plan • The observed responses in non-injected tumors during our clinical trials suggests that an anti-tumor immune response may be generated against tumor neoantigens released from tumor cells killed by Proxinium • Opdivo® and Keytruda® have been approved for

  35. Slide 35: De-Immunized Systemic Product Pipeline

    De-Immunized Systemic Product Pipeline Bouganvillea sp. deBouganin toxin 35

  36. Slide 36: deBouganin Pre-clinical Overview

    deBouganin Pre-clinical Overview • Highly potent plant toxin • Picomolar killing, avoidance of MDR, potentially effective against cancer stem cells • Safety profile provides broad therapeutic window • Engineered a de-immunized variant for systemic delivery • Type 1 ribosome inactivating protein • RN

  37. Slide 37: deBouganin vs. DM1

    • deBouganin conjugated to Herceptin is more potent than T- DM1 (Herceptin-DM1) nM 0.01 0.1 1 10 % S ur vi val +/- S .E 0 20 40 60 80 100 120 T-DM1 Her-deBoug Potency against individual 3+ HER2 cell lines nM 0.01 0.1 1 10 100 1000 10000 % S ur vi va l + /- S .E 0 20 40 60 80 100 120 T-DM1 DM1 nM 0.0

  38. Slide 38: Potential Advantages of deBouganin

    nM # o f m am m o sp h er es + /- S .E 0 20 40 60 80 NT T-DM1 Herc-deB 0 0.1 1 10 • Herceptin-deBouganin is more potent than T-DM1 against tumor cells with cancer stem cell properties • Targeted deBouganin is designed to avoid MDR mechanisms (e.g. PgP-1 overexpression) Cell line MDR Status IC50 (nM)

  39. Slide 39: Phase 1 trial in solid tumor subjects

    • Completed Two Dose Cohorts in Phase 1 trial in Solid Tumor Subjects • Primary tumor types: kidney, ovary, breast, stomach, pancreas, non small cell lung, thyroid and colorectal • Immunogenicity • No significant antibody response against the de-immunized bouganin • But 6/15 subjects (40%) exhibited

  40. Slide 40: VB6-845d: Intend to File IND with FDA in 2017

    VB5-845 ( m g/mL) 0 5 10 15 20 25 M ea n F o ld I n c reas e 0 10 20 30 40 50 VB6-845 VB6-845d VB6-845d retains binding specificity in pre-clinical study % p o sit ive -d o n o rs 0 5 10 15 20 25 30 95 100 WT D 22% 4% 845 Fab 845d Fab Successful de-immunization of 845 Fab to create VB6-845d <10% = l

  41. Slide 41: Upcoming Milestones

    Vicinium NMIBC Phase 3 initiation 2016 Initiate Proxinium / Checkpoint SCCHN Phase 2 trial 1H 2017 Vicinium NMIBC Phase 3 full enrollment 1H 17 Submit IND to FDA for systemic product candidate VB6-845d 2017 Vicinium NMIBC Phase 3 topline data 1H 18  Upcoming Milestones 41

  42. Slide 42: Eleven Biotherapeutics

    /SELEVEN BIOTHERAPEUTICS Targeting Cancer With POWER+PRECISION |

Eleven Biotherapeutics — Investor Presentation (January 2017) on 6ix